Patients with HCV genotype 2 or 3 infection ( n = 151 ) , enrolled at research centers in North America , Europe , or Australia , were assigned randomly to groups given 12 or 16 weeks of daclatasvir ( 60 mg once daily ) , or 24 weeks of placebo , each combined with peginterferon alfa-2a and ribavirin .